Clinigen to acquire SSI Strategy from Amulet Capital.

Clinigen, a pharmaceutical services company, agreed to acquire SSI Strategy, a company that operates as a life sciences consultancy, from Amulet Capital, a private equity firm. Financial terms were not disclosed. “Our purpose has always been to be the global pathfinder that transforms patient access to critical medicines. This key acquisition is a major step forward in operationalising that purpose by combining the best of both worlds for our clients. With SSI’s incredible strategic depth and our unmatched global operational reach in clinical trials supplies, managed access, and specialised commercialisation, we will be an even stronger, more complete partner for the entire product lifecycle, empowering our biopharma clients to bring life-changing medicines to patients faster,” Dr. Varun Sethi, Clinigen CEO.